The comparison of favipiravir and lopinavir/ritonavir combination in COVID-19  treatment

Çınarka, Halit; Günlüoğlu, Gülşah; Çörtük, Mustafa; Yurt, Sibel; Kiyik, Murat; Koşar, Filiz; Tanrıverdi, Elif; Arslan, Melih Akay; Baydili, Kürşad Nuri; Koç, Aysu Sinem; Altın, Sedat; Çetınkaya, Erdoğan

doi:10.3906/sag-2012-189

Cited by 3 publications

(3 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Cinarka and colleagues have shown that favipiravir is more effective than lopinavir-ritonavir in terms of mortality reduction in hospitalized patients with COVID-19. 12 In another study from Shenzhen, China, patients on favipiravir treatment had a significantly shorter viral clearance time and radiologic improvement was better versus patients on lopinavir-ritonavir treatment. 8 To date, there have been no studies published on favipiravir use in the KT population.…”

Section: Discussionmentioning

confidence: 99%

Favipiravir Use in Kidney Transplant Recipients with COVID-19: A Single-Center Experience

Kaya

Ataş²,

Tigen³

et al. 2022

Exp Clin Transplant

View full text Add to dashboard Cite

Objectives: Kidney transplant recipients are among the high-risk groups for severe COVID-19. To date, no specific antiviral agent has proved uniformly effective against SARS-CoV-2. Favipiravir, the recommended drug by the Turkish Ministry of Health, was uniformly supplied to all patients diagnosed with COVID-19 by a positive nasopharyngeal swab polymerase chain reaction test. The aim of our study was to retrospectively compare our kidney transplant recipients treated with favipiravir who developed COVID-19 infection versus those not treated with favipiravir during the clinical course of the disease, with a special emphasis on the occurrence of side effects and adverse events. Materials and Methods: We included 37 consecutive kidney transplant recipients with a median age of 46 years (62.2% women). Recipients included 8 with deceased donors and 29 with living related donors; median posttransplant survival was 8.0 years (IQR, 5.5-12.5 years).Results: Twenty-six patients (70.3%) received favipiravir, and 11 (29.7%) did not. There were no statistically significant differences between the groups for baseline demographic characteristics and clinical and laboratory data, except that the favipiravir-treated patients were older and had a higher requirement of oxygen treatment. There were no statistically significant differences between the 2 groups for the course and outcome of COVID-19 infection with regard to adverse side effects/events associated with favipiravir. Laboratory data at baseline, day 7, and day 30 were also comparable between the groups. Conclusions: Although the efficacy of favipiravir for treatment of COVID-19 infection remains controversial, favipiravir is safe for kidney transplant recipients.

show abstract

Section: Discussionmentioning

confidence: 99%

Favipiravir Use in Kidney Transplant Recipients with COVID-19: A Single-Center Experience

Kaya

Ataş²,

Tigen³

et al. 2022

Exp Clin Transplant

View full text Add to dashboard Cite

show abstract

“…The report cited here is a good example of this. Another example is a previous comparative study of favipiravir therapy and other antiviral drugs [ 2 ].…”

Section: To the Editormentioning

confidence: 99%

Hematological Malignancy Patients, COVID-19, and Favipiravir

Mungmunpuntipantip¹,

Wiwanitkit

2021

Tjh

View full text Add to dashboard Cite

“…В ретроспективном исследовании сравнительной эффективности фавипиравира и лопинавира/ритонавира, в которое было включено 204 госпитализированных пациента, было показано преимущество фавипиравира по влиянию на летальность [14]. Необходимо отметить, что исследование носило ретроспективный характер, что накладывает выраженные ограничения.…”

Section: Introductionunclassified

Rationale for a New Outpatient Drug Therapy Algorithm in COVID-19 Patients Based on the Principle of «Multi-hit» Approach

Zykov

Sinitsyn

Rvacheva

et al. 2021

A&Ch

View full text Add to dashboard Cite

The aim of the work was to justify the algorithm of outpatient drug therapy in patients with COVID-19, based on the principle of «Multi-hit» Approach. The algorithm is based on the published results of clinical studies and observations, authors’ own practical experience in the use and management of more than 4 thousand patients diagnosed with COVID-19 of varying severity during the 2020 pandemic. The article substantiates a complex algorithm for the treatment of outpatients with COVID-19, which includes etiotropic, pathogenetic, and symptomatic components of therapy with different mechanisms of action. The described approach is the 1st stage (outpatient) of a complex algorithm for managing patients with COVID-19. It has been successfully implemented in the system of outpatient care for patients with novel coronavirus infections in several leading medical institutions in Russia. The authors believe that the developed algorithm for providing outpatient drug therapy for COVID-19, based on the principle of multiple exposure, may be useful in real clinical practice of managing patients with coronavirus infection.

show abstract

The comparison of favipiravir and lopinavir/ritonavir combination in COVID-19 treatment

Cited by 3 publications

References 6 publications

Favipiravir Use in Kidney Transplant Recipients with COVID-19: A Single-Center Experience

Favipiravir Use in Kidney Transplant Recipients with COVID-19: A Single-Center Experience

Hematological Malignancy Patients, COVID-19, and Favipiravir

Rationale for a New Outpatient Drug Therapy Algorithm in COVID-19 Patients Based on the Principle of «Multi-hit» Approach

Contact Info

Product

Resources

About